Nebenwirkungen · Apixaban Accord
Apixaban Accord 2.5 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 14–15
HOS-146660 · Präparat HOS-099542
14 System organ class Prevention of Prevention of Treatment of Treatment of VTE in adult stroke and DVT and PE, VTE and patients who systemic and prevention prevention of have embolism in of recurrent recurrent undergone adult patients DVT and PE VTE in elective hip or with NVAF, (VTEt) in adult paediatric knee with one or patients patients from replacement more risk 28 days to surgery factors less than (VTEp) (NVAF) 18 years of age Haematochezia Uncommon Uncommon Uncommon Common Rectal haemorrhage, gingival Rare Common Common Common bleeding Retroperitoneal haemorrhage Not known Rare Not known Not known Hepatobiliary disorders Liver function test abnormal, Uncommon Uncommon Uncommon Common aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased Gamma-glutamyltransferase Uncommon Common Common Not known increased Alanine aminotransferase Uncommon Uncommon Common Common increased Skin and subcutaneous tissue disorders Skin rash Not known Uncommon Common Common Alopecia Rare Uncommon Uncommon Common Erythema multiforme Not known Very rare Not known Not known Cutaneous vasculitis Not known Not known Not known Not known Musculoskeletal and connective tissue disorders Muscle haemorrhage Rare Rare Uncommon Not known Renal and urinary disorders Haematuria Uncommon Common Common Common Anticoagulant-related Not known Not known Not known Not known nephropathy Reproductive system and breast disorders Abnormal vaginal haemorrhage, Uncommon Uncommon Common Very urogenital haemorrhage common§ General disorders and administration site conditions Application site bleeding Not known Uncommon Uncommon Not known Investigations Occult blood positive Not known Uncommon Uncommon Not known Injury, poisoning and procedural complications Contusion Common Common Common Common
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-27T13:45:00Z · SHA-256 d61ca619dbc3cc41b936fd00150a7483792c8b53e4c986c4c86af1cceab6e2ab · Passage 95919e100b005e10fd2708d410695dfceb2f824d9384908a6d23377601c836c3 · Zeichen 5683–9044 im Abschnitt